In healthy skin, epidermis and dermis are anchored together at the dermal-epidermal junction (DEJ), a specialized basement membrane pivotal for skin integrity and function. However, increased inflammation in the DEJ is associated with the disruption and separation of this junction and subepidermal blistering. Granzyme B (GzmB) is a serine protease secreted by immune cells. Dysregulated inflammation may lead to increased GzmB accumulation and proteolysis in the extracellular milieu. Although elevated GzmB is observed at the level of the DEJ in inflammatory and blistering skin conditions, the present study is the first to explore GzmB in the context of DEJ degradation in autoimmune sub-epidermal blistering. In the present study, GzmB induced separation of the DEJ in healthy human skin. Subsequently, α6/β4 integrin, collagen VII, and collagen XVII were identified as extracellular substrates for GzmB through western blot, and specific cleavage sites were identified by mass spectrometry. In human bullous pemphigoid, dermatitis herpetiformis, and epidermolysis bullosa acquisita, GzmB was elevated at the DEJ when compared to healthy samples, while α6/β4 integrin, collagen VII, and collagen XVII were reduced or absent in the area of blistering. In summary, our results suggest that regardless of the initial causation of sub-epidermal blistering, GzmB activity is a common final pathway that could be amenable to a single targeted treatment approach.
GzmB cleaves α6 and β4 integrins in vitro in domains pivotal for their function. Once we ascertained GzmB presence at the level of the DEJ in diseased skin, we hypothesized that GzmB mediates cleavage of α6/β4 integrin, collagen VII, and collagen XVII, which are important components of the basement membrane critical for DEJ function. Both α6 and β4 integrin sub-units were cleaved by GzmB ( Fig. 2a,b) ; α6 integrin was detected at 150 kDa with fragments at ~20, 25, and 37 kDa, whereas cleavage of β4 integrin ectodomain (100 kDa) yielded an evident fragment at ~65 kDa and a weaker band at 50 kDa. To confirm that cleavage of these DEJ components was indeed mediated by GzmB, compound 20, a GzmB-specific competitive inhibitor, and serpin A3N, an irreversible serine protease inhibitor, were included in the cleavage assay. Both inhibitors prevented the cleavage of α6 and β4 integrin sub-units at 100 μM and 600 nM respectively ( Fig. 2a,b ). Furthermore, mass spectrometry by ATOMS was used to identify cleavage sites on these proteins to assess whether GzmB-mediated cleavage of α6 and β4 integrins could impair DEJ function. We focussed on the extracellular domains of α6 and β4 integrins as this protein region is more likely to be exposed to GzmB. α6 integrin was cleaved by GzmB at Asp100, Asp166, Asp199, Asp302, Asp311, Asp358, Asp482, and Asp488 in the FG-GAP repeats 2, 3, 4, 5, and 7 within the extracellular β-propeller domain ( Fig. 3a and Supplemental Fig. S1 ), a cleavage site at Glu856 was also detected. Cleavage of the β4 integrin sub-unit fell within the Von Willebrand factor A domain at Glu223, Asp237 and Asp272, as well as within the Cysteine Rich Region 1 at Asp611, and within the linker region between these two domains at Asp351, Asp442 and Asp447 ( Fig. 3b and Supplemental Fig. S2 ).
GzmB cleaves collagen VII in ligand binding regions. Western blot was used to assess cleavage of collagen VII domain a.a 199-482 by GzmB. This fragment is part of the non collagenous region 1 (NC1), which is pivotal for collagen VII interactions with other proteins of the ECM 19, 20 . Untreated collagen VII fragment was detected at ~30 kDa, and its cleavage by GzmB yielded bands at ~20 and 25 kDa (Fig. 2c ). On the other hand, collagen I, the most common collagen in the human body, was not cleaved by GzmB ( Supplemental Fig. S3 ). Inhibition of collagen VII cleavage with serpin A3N prevented the appearance of both ~20 and 25 kDa bands, whereas compound 20 inhibition was incomplete and a cleavage band could still be detected at ~25 kDa ( Fig. 2c ).
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As for the location of cleavage, the NC1 fragment of collagen VII we tested was cleaved by GzmB in the Von Willebrand factor A domain at Asp193, in the fibronectin-like domain III-2 at Glu332 and Asp390, and within fibronectin-like domain III-3 at Asp414 ( Fig. 3c and Supplemental Fig. S4 ).
Collagen XVII is a substrate for GzmB cleavage. As a crucial component of the hemidesmosomes, collagen XVII plays a critical role in bridging the intracellular and the extracellular structural elements involved in epidermal adhesion 21 . Treatment of collagen XVII ectodomain (a.a 490-1497) with GzmB resulted in cleavage of this region, and in the appearance of a cleavage band at ~95 kDa (full length protein ~120 kDa). Pre-incubation of GzmB with both compound 20 and serpin A3N prevented NC16 cleavage ( Fig. 2d ). ATOMS was attempted on collagen XVII using 1 or 2 µg of protein. GzmB-digested and undigested forms of collagen XVII were compared by labeling exposed N-termini with heavy ( 13 CD 2 O formaldehyde) and light ( 12 CH 2 O formaldehyde) dimethylated tags respectively. However, detection of N-terminal peptides was confounded due to ion suppression by more intense ions from other contaminating proteins in the sample. Furthermore, agglutination of collagen XVII was observed after dimethylation, which likely decreased the efficiency of trypsin digestion. For these reasons, we were unable to obtain cleavage site data for this protein.
α6/β4 integrin, collagen VII and collagen XVII lining at the DEJ are disrupted in diseased skin. Following western blot and ATOMS analyses indicating that both α6 and β4 integrin sub-units, collagen VII and collagen XVII are substrates for GzmB, we sought to assess their integrity in bullous pemphigoid, dermatitis herpetiformis, and EBA skin samples. Staining for α6 integrin in normal skin was mainly localized perivascularly in the dermis and as a continuous line at the DEJ. When diseased skin samples were investigated, the pattern of α6 integrin localization was similar for all conditions, exhibiting scattered staining throughout the entire sections, which could be indicative of protein fragmentation ( Fig. 4) . At the DEJ, staining was absent, weak, or disorganized both in areas of epidermal detachment and in sections where the epidermis was still attached to the dermis ( Fig. 4 ). As for integrin β4, a strong well localized staining delineated the DEJ in healthy skin, as well as in bullous pemphigoid and dermatitis herpetiformis in areas where the epidermis was anchored to the dermis ( Fig. 4 ). However, integrin β4 staining was completely absent or faint in areas of epidermal separation in all conditions studied ( Fig. 4 ).
Mooney et al. have previously shown fragmented collagen VII in the DEJ of patients with discoid lupus erythematosus 22 . While normal skin displayed a continuous, strong staining for collagen VII lining the interface between epidermis and dermis ( Fig. 4 ), in bullous pemphigoid and dermatitis herpetiformis collagen VII staining was weak or absent. Weak staining in both diseases was localized on the dermal side of a blister or papillary abscess, consistent with a separation of the fibrillar zone of the DEJ from the lamina densa above it due to cleavage of collagen VII in the NC1 (Fig. 4 ). In dermatitis herpetiformis, collagen VII staining presented a peculiar pattern, with short stained sections perpendicular to the epidermis rather than parallel to it. Collagen VII staining of EBA samples showed an intermittent pattern, with DEJ segments presenting weak staining alternated by areas with a stronger staining ( Fig. 4) . Finally, collagen XVII staining pattern for all conditions was similar to what was observed for the other substrates. A clear, uninterrupted line of staining was detected in healthy skin, whereas in diseased skin weak staining was observed in areas of reduced DEJ integrity and was mostly absent in the sections of skin where the epidermis had detached ( Fig. 4 ).
Incubation with GzmB results in epidermal separation in healthy human skin and is inhibited by Compound 20.
As GzmB is elevated at the DEJ of bullous pemphigoid, dermatitis herpetiformis, and EBA, and capable of cleaving key junctional proteins, the direct impact of GzmB proteolysis on DEJ integrity in freshly-isolated human skin was assessed. A ~1 mm × 4 mm strip of healthy skin comprising epidermis and dermis was immersed and incubated for 12 h at 37 °C in a 200 nM solution of GzmB. Upon incubation, the skin was viable but H&E staining revealed the appearance of clefts between the epidermis and the dermis in the GzmB-treated sample that were mostly absent in the PBS control ( Fig. 5 and Supplemental Fig. S9 ). Inactivation of GzmB with the GzmB-specific inhibitor Compound 20 prevented the formation of DEJ clefts, revealing a tissue morphology similar to PBS control ( Fig. 5 ).
Discussion
It is now widely acknowledged in the literature that extracellular GzmB exerts a pathogenic, perforin-independent, role in conditions associated with dysregulated and/or chronic inflammation and impaired tissue repair due to ECM cleavage 7,16,23-25 . In the present study, we used western blot and ATOMS to show for the first time that α6/ β4 integrin and collagen VII, which are key components of the DEJ, are cleaved by GzmB in key regions for their anchoring functions. We also demonstrated that in diseased human skin biopsies of bullous pemphigoid, dermatitis herpetiformis and EBA, sub-epidermal blisters display elevated levels of GzmB at the DEJ accompanied by degradation of the newly discovered GzmB substrates α6/β4 integrin, collagen VII, and collagen XVII. Supporting the pathological relevance of GzmB activity, we reported partial detachment of the epidermis from the dermis in healthy human skin exposed to a physiologically relevant concentration of GzmB 26, 27 , and showed that this separation can be prevented by a GzmB-specific inhibitor. These data suggest that, in addition to previously studied proteases 28 , extracellular GzmB could also contribute to epidermal separation in autoimmune sub-epidermal blistering pathologies.
Evidence for the importance of α6/β4 integrin comes from both animal models 29 and from severe, often lethal, human blistering diseases. Mutations and deficiencies of the integrin complex involving α6/β4, as well as production of anti-α6/β4 integrin auto-antibodies 30, 31 , contribute to lethal phenotypes characterized by widespread muco-cutaneous blistering. Several studies have identified mutations in the genes coding for α6/β4 integrin [32] [33] [34] or absence at the protein level of one of its sub-units 35 , in numerous subtypes of epidermolysis bullosa. In particular, Phillips et al. speculated that in situ proteolytic cleavage of the epitopes by an as yet unidentified protease, might be responsible for the loss of β4 sub-unit immunoreactivity in patients with junctional epidermolysis bullosa 36 . In this study we show that GzmB cleaves both α6 and β4 integrin sub-units at several sites in their ligand-binding extracellular domains [37] [38] [39] [40] , possibly compromising the adhesive properties of this molecule. The importance of these extracellular regions is particularly evident for integrin β4 as collectively, most of the missense mutations and the amino acid deletions described in lethal junctional epidermolysis bullosa were located in its extracellular domain 32, [41] [42] [43] , while missense or splice mutations associated with the non-lethal form were frequently located in the cytoplasmic portion 41, 44, 45 . Interestingly, Nakano et al. identified the lethal mutation p.D131Y/p.G273D, which may abolish important ligand binding sites of integrin β4 as it falls within a highly conserved region 41 . Since one of the GzmB cleavage sites we have identified is at Asp272, this is suggestive that GzmB-mediated cleavage of α6/β4 integrin could likewise severely affect the adhesive properties of this molecule.
As the main component of the papillary dermis, another protein fundamental for the integrity of the DEJ is collagen VII. Among collagen VII domains, fibronectin-like regions are pivotal for the interaction with several ECM components. Studies with a recombinant version of the NC1 region revealed strong binding affinity of fibronectin-like domains with collagen I, collagen IV, laminin 332 and fibronectin 19, 20 , which allows anchorage of the papillary dermis to the lamina densa. Mutations of collagen VII or production of auto-antibodies against this region result in severe disruption of the DEJ, causing dystrophic epidermolysis bullosa and EBA respectively 46, 47 . These conditions are characterized by extensive epidermal detachment and formation of blisters. We show herein GzmB-mediated cleavage of collagen VII in the fibronectin-like III-2 domain, as well as in the von Willebrand factor A domain, and inhibition of this cleavage by the GzmB inhibitors serpin A3N and compound 20 48 . Moreover, GzmB-mediated cleavage of collagen XVII was also observed. Collagen XVII is another important component of the hemidesmosome, whose interaction with α6/β4 integrin is required for the assembly of protein complexes that anchor basal keratinocytes to the lamina lucida 44 . Taken together, these observations suggest that GzmB can disrupt the basal keratinocyte/lamina lucida connection through cleavage of α6/β4 integrin and collagen XVII, and lamina densa/fibrillar zone adhesion through cleavage of collagen VII.
GzmB accumulation at the DEJ is observed in bullous dermatoses such bullous pemphigoid 9 and dermatitis herpetiformis 10 , as well as in cutaneous adverse drug reactions including lichenoid drug eruption 49 , SJS/TEN and generalized bullous fixed drug eruption 11 . However, as the newly discovered, non-apoptotic roles for GzmB were not established at the time, none of the aforementioned studies considered extracellular GzmB-mediated proteolysis as a mechanism for DEJ disruption. Rather, GzmB was proposed to contribute to CD8 + T-cell-and NK-mediated, keratinocyte and melanocyte 50 apoptosis in a perforin-dependent manner. While mostly absent in normal skin, GzmB is present at the DEJ in the sub-epidermal blistering conditions bullous pemphigoid and dermatitis herpetiformis in agreement with previous studies 9-11 , and we have shown for the first time accumulation of this protease at the DEJ in EBA. It has long been hypothesized that anti-DEJ auto-antibody-triggered sub-epidermal blister formation is mediated by proteases secreted by infiltrating inflammatory cells 51 . Indeed, auto-antibody-mediated immune cell recruitment to the DEJ is a mandatory condition for dermo-epidermal separation as it dictates the localized and concentrated degranulation of proteinases 52 . Confirming this mechanism, auto-antibodies contained in the serum of patients with bullous pemphigoid 53 , EBA 54 , and pemphigoid gestationis 55 promote leukocyte recruitment to the DEJ resulting in its separation. We suggest that GzmB could be an important contributor to this DEJ separation in autoimmune conditions as the DEJ substrates we have identified are degraded proximal to the area in which blistering is occurring in these diseases. Although in vivo studies will be necessary to fully elucidate GzmB contribution to autoimmune skin blistering, further evidence for a role of GzmB in this process derives from our observation that incubation of healthy human skin with a physiologically relevant concentration of this protease results in clefts formation at the DEJ. One limitation of this model is that, unlike in diseased skin, staining for α6/β4, collagen VII, and collagen XVII remained detectable in areas of epidermal separation (data not shown). There are several explanations for this result. Firstly, in this model the entire skin section is bathed in a solution containing cationic GzmB, which is attracted to, and sequestered by negatively charged proteoglycans rather than concentrating at the DEJ, whereas in sub-epidermal blistering conditions, GzmB is directed specifically to the basement membrane by auto-antibodies. Thus, it is possible that in areas of mild epidermal separation observed in our ex vivo model the antibodies we used for IHC could still recognize their epitopes, while the lack of staining in diseased human samples characterized by complete epidermal detachment is a consequence of more severe protein degradation due to a long-term and DEJ-localized exposure to GzmB. Another explanation is that given this is a static environment, cleavage fragments likely remain in the DEJ and are subsequently detected by immunohistochemistry. Despite these limitations, this model shows a causative relation between GzmB exposure and epidermal separation, although not as widespread and dramatic as observed in vivo, providing proof of concept that GzmB alone can dramatically affect DEJ anchoring function.
The pathological role of extracellular GzmB in autoimmune diseases might not be limited to the physical disruption of important substrates. Growing evidence suggest that antigenic, GzmB-generated peptide fragments are part of a feed-forward loop that sustains the propagation of several autoimmune diseases (reviewed in 56 ). Studies suggest that GzmB is instrumental in auto-antigen generation in certain autoimmune conditions [57] [58] [59] . In our study, GzmB cleaves α6/β4 integrin and collagen VII in epitope regions recognized by auto-antibodies present in the sera of patients with certain pemphigoid diseases, and EBA respectively. In oral pemphigoid, one of the identified auto-epitopes is represented by the peptide a.a. 292-305 of α6 integrin 60 . In vitro, GzmB cleaves α6 integrin at residues Asp199 and Asp302, thus we speculate that GzmB could potentially generate this antigenic fragment in vivo, establishing a cycle of sustained immune response and further generation of antigenic fragments.
As mentioned above, we also observed GzmB-mediated cleavage of the ectodomain of collagen XVII. The production of collagen XVII auto-antibodies results in bullous pemphigoid 61, 62 whereas mutations in the ectodomain of this protein have been associated with certain forms of junctional epidermolysis bullosa 63, 64 . Although we were not able to identify the specific GzmB cleavage sites in the NC16 region of collagen XVII, this domain is the immunodominant region in bullous pemphigoid and its recombinant forms are used for detecting specific auto-antibodies in approximately 85% of patients affected by this condition 65, 66 .
Finally, several groups have demonstrated that in EBA, T and B cells target identical regions of the NC1 domain of collagen VII 67, 68 . In particular, Lapiere et al. incubated different fragments of collagen VII with sera from 19 EBA patients, and observed that 16 sera strongly reacted with the fusion protein composed of the fibronectin-like III domains 1 to 4 69 . The NC1 domain of collagen VII also mediates Fc-dependent neutrophil activation and induction of dermo-epidermal separation 54 .
Given the presence of GzmB cleavage sites in the immunodominant regions of α6/β4 integrin, collagen XVII, and collagen VII, this protease may contribute to the generation of antigenic peptides either directly, or by revealing a cryptic epitope due to a change in substrate structure. If confirmed, this hypothesis would have substantial therapeutic relevance as the molecular target of GzmB includes, but is not limited to the antigenic target of the auto-antibodies. Thus, even though the disease-defining antigenic targets are all different, they result in a common final pathway that may be amenable to the single targeted treatment approach of inhibiting GzmB.
In summary, the present study suggests for the first time that GzmB mighty directly contribute to sub-epidermal autoimmune blistering via extracellular proteolysis-mediated DEJ impairment, thus playing a role in this pathological process that goes beyond cytotoxicity. Inhibition of GzmB represents a novel therapeutic approach for the treatment and prevention of autoimmune sub-epidermal blistering.
Materials and Methods
All human studies were approved by the University of British Columbia Review Ethic Board (H15-03345). Waiver of consent was obtained as per Tri-Council Policy Statement article 12.3B.
Immunohistochemistry and Histology on Diseased Skin. Paraffin-embedded skin samples from patients affected by bullous pemphigoid (N = 3), dermatitis herpetiformis (N = 3), and inflammatory EBA (N = 3) were sectioned (5 μm) for immunohistochemical analysis of GzmB (Cat # ab4059, ABCAM) and collagen VII (Cat # ab93350, ABCAM, Toronto, ON) using 3,3′-Diaminobenzidine for visualization, as well as α6 (Cat # ab181551, ABCAM) and β4 (Cat # ab182120, ABCAM) integrins, and collagen XVII (NC16a-3 70 ) visualized through Novared ® . Healthy skin obtained from patients undergoing elective abdominoplasty was used as a control. In order to observe cellular infiltrate and tissue architecture, H&E staining was also performed using established methods. Following image acquisition, these H&E stained sections were de-stained by serial incubation in xylene (2 min), 100% EtOH (2 min), 95% EtOH (2 min), water (10 min), and acidic alcohol solution (10 min). In order to detect GzmB-producing cells, de-stained H&E sections were probed for GzmB (Cat # ab4059, ABCAM). All slides were scanned using a Aperio CS2 slide scanner (Leica, Concord, ON).
DEJ Proteins Cleavage Assay. The recombinant human integrin α6/β4 (α6 a.a. 24-878, β4 a.a. 28-710, Cat # 5497-A6-050, R&D Systems, Minneapolis, MN), collagen VII (199-482 a.a., Cat # 2018615, MyBiosource, San Diego, CA), collagen XVII ectodomain (490-1497 a.a., generous gift from Dr. Claus-Werner Franzke), and collagen I (Cat # NBP1-97266, Novus Biologicals, Littleton, CO) were incubated for 24 h at 37 °C in 200 nM purified human GzmB (EmeraldBio, Bainbridge Island, WA). For inhibition studies, prior to the addition of substrates to the reaction, GzmB was incubated in the presence of 600 nm serpin A3N (generous gift from Dr. Chris R. Bleackley, University of Alberta, Edmonton, AB, Canada) or 100 μM of the small molecule inhibitor compound 20 (courtesy of the Centre for Drug Research and Development, Vancouver, BC) for 1 h at 37 °C. After the 24 h incubation, proteins were denatured, separated on a 4-20% (for integrin α6/β4), 10% (for collagen VII), 8-10% (for collagen XVII), or 7.5% (for collagen I) SDS-polyacrylamide gel. Cleavage was detected by western blot using anti-human integrin α6 sub-unit (Cat # ab181551, ABCAM), anti-human integrin β4 sub-unit (Cat # MAB4060, R&D Systems, Minneapolis, MN), anti-collagen VII (Cat # ab93350, ABCAM), NC16A antibody directed against the NC16A domain of human collagen XVII 71 and imaged using a Li-Cor Odissey FC (Li-Cor, Lincoln, NE). Coomassie staining was used for the assessment of collagen I cleavage following manufacturer instructions.
LC-MS/MS analysis.
GzmB cleavage sites were identified by ATOMS as described earlier 17, 18 . Briefly, GzmB-digested or control substrates were denatured, cysteines reduced with dithiothreitol and alkylated with iodoacetamide. Primary amine groups were dimethylated with formaldehyde and sodium cyanoborohydride before acetone precipitation. Pellets were redissolved in digestion buffer with 1 μg/mL MS-grade trypsin (Thermo Fisher Scientific, Waltham, MA) and desalted using StageTips 72 . Samples were analyzed on an Impact II Q-TOF (Bruker, Billerica, MA) on ReproSilPur 120 C18-AQ 1.9 μm particles (Dr. Maisch) columns and resolved by a gradient of acetonitrile (0.1% v/v formic acid) in water delivered by an easy-nLC system (Thermo Fisher Scientific) preceding data-dependent precursor selection of the top 18 peaks. Spectra were extracted using DataAnalysis 4.3 (Bruker) and searched against a Uniprot human proteome database (downloaded 2016-02-24; 70,472 sequences) using semi-specific ArgC as enzyme specificity, carbamidomethylation (C) and dimethylation (K) as fixed modifications, and deamidation (N,Q), dimethylation (N-term), pyroglutamation (Q) and oxidation (M) as variable Scientific RepORtS | (2018) 8:9690 | DOI:10.1038/s41598-018-28070-0 modifications. Potential GzmB cleavage sites were defined as semi-specific, N-terminally dimethylated peptides with an acidic residue N-terminal to the identified sequence identified at a peptide expect value <0.01. Skin Cleavage Assay. Fresh healthy human skin obtained from patients undergoing elective plastic surgery was transported to the lab and cut into ≈1 mm × 4 mm strips (N = 3). The adipose tissue layer was removed to obtain a strip of dermis and epidermis. Skin strips were then incubated at 37 °C for 12 h in 300 μL of either PBS, 200 nM GzmB, or 200 nM GzmB previously inactivated through 1 h incubation at 37 °C with 100 μM Compound 20. Following incubation, samples were fixed in 10% buffered formalin overnight, paraffin embedded and sectioned for H&E staining using established methods, and TUNEL (cell death) analysis following manufacturer's instructions (Cat # 11684795910, Sigma). Outermost sections of the samples were used for staining, as GzmB might not penetrate deep into the tissue.
